Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1504 participants.

Also called NCT01159600

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,504 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01159600
  • EudraCT 2009-016258-41
Other papers using this trial's data
  • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes care, 2013-11 DOI, PubMed 23963895, PMC3816918 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
United States, Canada, China, France, Germany, India, Mexico, Slovakia, Slovenia, South Korea, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01159600. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2014-06-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo identical to BI 10773 high dose
Intervention (Drug)
Placebo identical to BI 10773 low dose
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo identical to BI 10773 low dose
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo identical to BI 10773 high dose
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01159600
Content hash
472b3619b759d7b3cb4ea0440c90cf0a5090e62dbf5c786a7f530cf49f669661